Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alterity Therapeutics ( (AU:ATH) ) has issued an announcement.
Alterity Therapeutics reported a 66.3% increase in revenue for the year ending June 30, 2025, reaching A$446,291, primarily from interest received. Despite a net loss of A$12,147,828, the company improved its financial position with a significant cash increase to A$33,158,642. This financial performance highlights Alterity’s ongoing commitment to its core activities without significant changes, although no dividends were declared for the year.
More about Alterity Therapeutics
Alterity Therapeutics Limited is an Australian company focused on developing disease-modifying treatments for neurodegenerative diseases. The company operates through its subsidiaries in the United States and the United Kingdom, maintaining a strong presence in the healthcare industry.
YTD Price Performance: 30.0%
Average Trading Volume: 13,877,320
Technical Sentiment Signal: Sell
Current Market Cap: A$110.5M
Learn more about ATH stock on TipRanks’ Stock Analysis page.